Citigroup Maintains Buy on CRISPR Therapeutics, Raises Price Target to $88
Benzinga Newsdesk 3 months ago
NewsPrice TargetAnalyst Ratings
Citigroup analyst Yigal Nochomovitz maintains CRISPR Therapeutics (NASDAQ:CRSP) with a Buy and raises the price target from $82 to $88.
Citigroup analyst Yigal Nochomovitz maintains CRISPR Therapeutics (NASDAQ:CRSP) with a Buy and raises the price target from $82 to $88.